Medications for Coronary Artery Disease: Complete Drug Class Guide
Coronary artery disease (CAD) management requires a multi-drug approach targeting atherosclerosis progression, thrombosis prevention, symptom control, and risk factor modification. Contemporary guidelines (ACC/AHA/ESC) emphasize evidence-based combination therapy.
1. Antiplatelet Therapy (Thrombosis Prevention)
| Drug | Mechanism | Indication | Key Points |
| Aspirin 81 mg | COX-1 inhibition → ↓TXA₂ | All CAD (primary/secondary prevention) | Lifelong unless contraindicated; GI bleeding risk |
| Clopidogrel | P2Y₁₂ inhibition | ACS, PCI/stent, aspirin intolerance | CYP2C19 loss-of-function alleles reduce efficacy |
| Ticagrelor | Reversible P2Y₁₂ inhibition | ACS, post-MI | Faster onset/offset; dyspnea side effect; BID dosing |
| Prasugrel | Irreversible P2Y₁₂ inhibition | ACS with PCI | Contraindicated if prior stroke/TIA; bleeding risk |
DAPT duration: 12 months post-ACS/PCI (shorter if high bleeding risk; longer if high ischemic risk)
2. Statins (Lipid Lowering / Plaque Stabilization)
- High-intensity: Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg → ≥50% LDL reduction
- Moderate-intensity: Atorvastatin 10-20, Rosuvastatin 5-10, Simvastatin 20-40 → 30-49% LDL reduction
- Goal: LDL <70 mg/dL (very high risk) or <55 mg/dL (extreme risk per ESC)
- Pleiotropic effects: Anti-inflammatory, plaque stabilization, endothelial improvement
- Add-ons: Ezetimibe, PCSK9 inhibitors (evolocumab, alirocumab), bempedoic acid if not at goal
3. Blood Pressure Control
ACE Inhibitors
- Lisinopril, ramipril, enalapril, perindopril
- Indications: CAD + HTN, diabetes, CKD, HFrEF, post-MI
- Benefits: Reduce mortality, MI, stroke; regress LVH
- Monitor: K⁺, creatinine, cough, angioedema
ARBs (ACEi Alternative)
- Losartan, valsartan, candesartan, olmesartan
- Similar indications; no cough; less angioedema
- Valsartan/sacubitril (ARNI) for HFrEF
Beta-Blockers
- Metoprolol succinate, carvedilol, bisoprolol, nebivolol
- Mortality benefit: Post-MI, HFrEF, hypertension
- Mechanism: ↓HR, ↓contractility, ↓O₂ demand, antiarrhythmic
- Post-MI: Initiate early; continue indefinitely
Calcium Channel Blockers
- Dihydropyridines: Amlodipine (vasoselective) — HTN, vasospastic angina
- Non-DHP: Verapamil, diltiazem — rate control, HTN (avoid in HFrEF)
Mineralocorticoid Receptor Antagonists
- Spironolactone, eplerenone — HFrEF, resistant HTN
4. Antianginal Therapy (Symptom Control)
- Nitrates: Sublingual (acute), long-acting (isosorbide mononitrate), patches — venodilation ↓preload, coronary dilation
- Ranolazine: Late Na⁺ current inhibition — improves diastolic function; no HR/BP effect
- Ivabradine: If sinus rhythm, HR ≥70 on max beta-blocker — HFrEF, chronic angina
- Trimetazidine: Metabolic modulator (shifts to glucose oxidation)
5. Emerging / Adjunctive Therapies
- SGLT2 inhibitors (empagliflozin, dapagliflozin): CV death/HF hospitalization reduction in T2D + CAD; now indicated for HF regardless of DM
- GLP-1 RAs (semaglutide): MACE reduction in T2D + ASCVD
- Colchicine 0.5 mg: Anti-inflammatory; reduces recurrent events post-MI
- Omega-3 (icosapent ethyl 4g): High-risk TG 135-499 on statin
Treatment Algorithm Summary
- All CAD: Aspirin + high-intensity statin + lifestyle
- Post-MI/ACS: Add beta-blocker, ACEi/ARB, P2Y₁₂ inhibitor (DAPT)
- HFrEF: GDMT quad: ACEi/ARB/ARNI + beta-blocker + MRA + SGLT2i
- Angina: Add antianginals stepwise
- Risk factors: Treat to target (BP, LDL, glucose, weight, smoking)
Monitoring and Adherence
- Regular follow-up: lipids, renal function, LFTs, glucose, side effects
- Deprescribing when appropriate (e.g., DAPT completion)
- Shared decision-making for elderly/frail (polypharmacy, fall risk)
Key principle: CAD medication is not "one size fits all." Regimen intensity matches ischemic/bleeding risk, comorbidities, and patient preferences. Regular reassessment ensures optimal benefit-risk balance.
Cardiovascular Disease - Related Articles